<DOC>
	<DOCNO>NCT00004207</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness liposomal daunorubicin treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Liposomal Daunorubicin Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose daunorubicin liposomal patient metastatic breast cancer . II . Assess antineoplastic activity safety profile regimen patient . OUTLINE : This dose escalation study . Patients receive daunorubicin liposomal IV minimum 2 hour day 1 . Treatment repeat every 3 week maximum 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos daunorubicin liposomal maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity . Patients stable respond disease follow 1 3 month , every 3 month 1 year . PROJECTED ACCRUAL : Approximately 15-20 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven metastatic breast cancer Measurable disease No bone metastases No CNS involvement leptomeningeal disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) AST ALT less 2 time ULN ( less 5 time ULN liver metastasis present ) Renal : Creatinine normal Cardiovascular : Left ventricular ejection fraction least 50 % normal echocardiogram MUGA scan No active ischemic heart disease No uncontrolled hypertension No poorly control atrial arrhythmia , symptomatic angina pectoris , myocardial infarction within past 6 month No symptomatic congestive heart failure , percutaneous transluminal coronary angioplasty , coronary artery bypass graft surgery within past 12 month Other : No primary cancer within past 5 year except curatively treat nonmelanomatous skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No condition would preclude informed consent compliance PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior immunotherapy No prior bone marrow transplantation Chemotherapy : Prior nonanthracycline base chemotherapy breast cancer allow No prior anthracycline base chemotherapy metastatic disease Prior anthracycline base adjuvant chemotherapy allow : At least 6 month elapse completion adjuvant therapy detection metastatic disease Cumulative dose great 300 mg/m2 Endocrine therapy : At least 3 week since prior hormonal therapy No concurrent hormonal corticosteroid therapy breast cancer Radiotherapy : At least 2 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>